⬆️prevalence of HCQ retinopathy: Kaiser Permanente 676 pts retrospect study #OP0133 👉6.8% (n=46) had HCQ retinopathy w/ risks: 👉age>80 (OR 3.83) 👉h/o atherosclerosis (OR 2.99), 👉cum. dose >2000 mg (OR 15.8) 👉10-15 yrs use (OR 4.44) 👉>15 yrs (OR 19) #EULAR2021 @rheumnow https://t.co/QA8HHXdnjL

Which drug are you most excited about changing future treatments in SLE? #EULAR2021 @RheumNow

Based on the data, what would you do in a new SLE patient w/LN class IV who is already on a background of GC's+HCQ? @rheumnow @kidneydoc101 @Lupusreference

The case for starting combo Rx for LN (rather than sequential Rx): 👉Aurora trial: voclosporin + MMF (vs. MMF only) prompt efficacy on proteinuria across all ethnic subgroups, twice more complete renal response , no major safety signals. slide 1/ #EULAR2021 @rheumnow https://t.co/TA5i9ITuL7

OP0131: Pooled data from TULIP-1 and TULIP-2 show anifrolumab (anti-IFN receptor Ab) show improvement of rash and arthritis. Shows promise for drug, particularly in subset of pts with high IFN activity #EULAR2021 @RheumNow https://t.co/sddF2NRlEg